Trials / Terminated
TerminatedNCT04698915
Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer
GRECO-2: A Randomized, Phase 2b Study of GC4711 in Combination With Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Unresectable or Borderline Resectable Nonmetastatic Pancreatic Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 177 (actual)
- Sponsor
- Galera Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
GTI-4711-201 is designed as a Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the effect to OS by adding GC4711 to SBRT following chemotherapy in patients with unresectable or borderline resectable nonmetastatic
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Drug GC4711 | 15 Minute IV Infusion |
| DRUG | Placebo | 15 Minute IV Infusion |
Timeline
- Start date
- 2021-05-07
- Primary completion
- 2023-11-30
- Completion
- 2023-11-30
- First posted
- 2021-01-07
- Last updated
- 2024-05-21
- Results posted
- 2024-05-21
Locations
35 sites across 4 countries: United States, Canada, France, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04698915. Inclusion in this directory is not an endorsement.